

Human campylobacteriosis: a challenge for the veterinary profession

Sean F. Altekruse, DVM, PhD, DACVPM, and Linda K. Tollefson, DVM, MPH

Historical Aspects and Current Problems

The first description of a bacterium belonging to the genus *Campylobacter* is attributed to Theodore Escherich at the end of the 19th century.¹ At the beginning of the 20th century, infections with *Campylobacter* spp, described as a related *Vibrio*, were recognized to cause abortions in sheep. Only after a suitable isolation medium was developed in the 1970s were 2 closely related pathogens, *C jejuni* and *C coli*, recognized to be common human enteric pathogens.² In humans, *C jejuni* causes approximately 90% of confirmed enteric *Campylobacter* infections.^{3,4}

In a 1999 report,⁵ the national Centers for Disease Control and Prevention estimates that there are 2.5 million human cases of campylobacteriosis in the United States per year. Although there has been a decline of approximately 27% in the incidence of campylobacteriosis in FoodNet surveillance sites between 1996 and 2001, *Campylobacter* spp remain among the most common bacterial causes of foodborne infection.⁶ Postinfectious sequelae of infection include Guillain-Barré syndrome (GBS) and reactive arthritis. Challenges for the veterinary profession include implementation of pathogen reduction measures across the food chain and prevention of foodborne and zoonotic infections and infections caused by fluoroquinolone-resistant *Campylobacter* strains. This report provides an outline of the illness in humans, risk factors for human infection, *Campylobacter* ecology, and potential control points to prevent human infections.

Human Illness

Although *C jejuni* and *C coli* can exist as commensal organisms of domestic poultry and livestock, they are considered human pathogens. In humans, the clinical spectrum of *Campylobacter* enteritis ranges from loose feces to dysentery. Self-limiting acute enteritis is the most common syndrome. Prodromal symptoms are common and include headache, low fever, and myalgia lasting from a few hours to a few days. Symptoms of acute infection often begin with abdominal cramps followed by diarrhea and high fever, peaking during the

first days of illness.⁷ *Campylobacter jejuni*-specific serum antibodies confer immunity to symptomatic infection; however, the duration of protective immunity is not known.^{8,9}

Complications of Infection

An estimated 100 people die of *C jejuni* infections each year in the United States. These fatal infections occur most often in infants, the elderly, or immunosuppressed individuals.⁵ Bacteremia is most often detected in patients with underlying disease¹⁰ and is a potentially fatal complication of HIV/AIDS.¹¹ Chronic diarrhea is also a complication of HIV-associated campylobacteriosis. The HIV-positive individuals who develop campylobacteriosis have shorter survival times and higher rates of bacteremia and hospitalization than HIV-positive individuals without campylobacteriosis.¹²

Sequelae of Infection

Guillain-Barré syndrome—With several thousand cases occurring each year, GBS is the most common cause of acute flaccid paralysis in the United States.¹³ Guillain-Barré syndrome is an acute immune-mediated disorder of the peripheral nervous system. Leg weakness is often the presenting sign, followed by ascending paralysis. After 1 year, 70% of patients make complete neurologic recovery, 22% partially recover, 8% remain unable to walk, and 2% remain bedridden or require ventilation. Most cases of GBS are believed to follow an infectious disease, and approximately 40% of those are thought to follow *Campylobacter* infection. Guillain-Barré syndrome is estimated to occur in 1 in every 1,000 patients infected with *Campylobacter*. Although a diverse group of strains is associated with GBS,¹⁴ the syndrome is strongly linked to a few strains of *C jejuni* (eg, heat-stable or Penner serotype HS:19 and HS:41).^{15,16} *Campylobacter* strains contain sialic acid linkages to lipooligosaccharides resembling sialic acid moieties on the gangliosides of peripheral nerve tissues.¹⁷ Patients with GBS develop antibodies against these gangliosides, resulting in autoimmune targeting of peripheral nerve sites. Complement-mediated damage¹⁸ and blockage of neurotransmission¹⁹ are suspected to affect GBS pathogenesis.

Many individuals are exposed to *C jejuni* strains that mimic gangliosides, and only a few develop GBS; therefore, host factors are suspected to contribute to GBS. In

From the Division of Cancer Epidemiology and Genetics, National Cancer Institute, 6120 Executive Blvd MSC 7234, Rockville, MD 20852 (Altekruse); and the Center for Veterinary Medicine, Food and Drug Administration, 7500 Standish Pl, Rockville, MD 20895 (Tollefson).

Address correspondence to Dr. Altekruse.

1 study,²⁰ *Campylobacter*-related GBS was associated with major histocompatibility antigen, HLA-DQB1*03; however, this association was not replicated in another well-designed study.¹⁵ Proposed treatments for GBS have not been fully evaluated in clinical trials but include treatment with corticosteroids, immunoglobulin, and plasmapheresis.²¹

Reactive arthritis—Reactive arthritis, or Reiter's syndrome, may also be a sterile sequela to acute gastrointestinal campylobacteriosis. Onset of reactive arthritis occurs 7 to 10 days after onset of diarrheal illness. The frequency of reactive arthritis as a sequela of campylobacteriosis has not been well described in the United States, but in Finland, 45 of 609 (7%) patients with laboratory-confirmed campylobacteriosis developed reactive arthritis.²² Arthritis was oligo- or poly-articular and in most cases mild. In the Finnish study, 37 of the 45 (82%) patients had *C jejuni* infections, and 8 (18%) had *C coli* infections. None of the patients with reactive arthritis were children. In a Danish study,²³ patients with joint pain had more severe gastrointestinal symptoms and longer duration of diarrhea than those without joint pain. Anti-*Campylobacter* antibody titers were similar in both patient groups. Antimicrobial treatment did not prevent reactive arthritis.

Fluoroquinolone resistance—The FDA has proposed to ban the use of fluoroquinolones in poultry in response to the emergence of fluoroquinolone-resistant *Campylobacter* strains as a cause of human infections in the United States. The FDA partially attributed this trend to veterinary use of fluoroquinolones,²⁴ concluding that use of fluoroquinolones in poultry compromises the clinical utility of fluoroquinolones in humans. An FDA risk assessment estimated that each year, thousands of people who are being treated with a fluoroquinolone are infected with fluoroquinolone-resistant *Campylobacter* strains after consuming or handling chicken, which may result in a prolonged duration of illness.²⁵

Fluoroquinolone-resistant *Campylobacter* strains were not detected in the United States in 1986, the year when this class of antimicrobials was first introduced for human use in the United States.²⁶ Resistance rates increased to 5% in the next few years. The proportion of *Campylobacter* isolates from humans who exhibited resistance to fluoroquinolones increased more rapidly after 1995, when fluoroquinolones were first approved by the FDA for the treatment of avian colibacillosis in poultry flocks. Since 1997, 14 to 18% of *Campylobacter* strains isolated from humans in the United States have been resistant to ciprofloxacin.²⁷ A study²⁸ by the Minnesota Department of Health suggested that the epidemiology of infection with fluoroquinolone-resistant *Campylobacter* strains shifted beginning in 1995 with the emergence of a domestic reservoir of fluoroquinolone-resistant *C jejuni*. In Minnesota, the molecular subtypes of fluoroquinolone-resistant *C jejuni* strains isolated from humans who had not traveled outside the United States matched the molecular subtypes of fluoroquinolone-resistant *C jejuni* isolated from locally purchased retail poultry products. An

increase in the frequency of infections with fluoroquinolone-resistant strains was also observed in the **National Antimicrobial Resistance Monitoring System (NARMS)**. Case-control studies conducted by NARMS revealed that chicken consumption is an important risk factor for infection with domestically acquired fluoroquinolone-resistant strains. Infections with such strains were also associated with longer duration of diarrhea and increased likelihood of hospitalization.⁴

Engberg et al²⁹ documented the emergence of fluoroquinolone-resistant *Campylobacter* strains as a cause of human infection in 10 developed nations during the 1990s in relation to the approval of this class of antimicrobial drugs for use in veterinary practice. Most fluoroquinolone resistance is caused by spontaneous point mutations in the DNA gyrase A subunit region that alters the fluoroquinolone-binding site.³⁰ Strains with this mutation have elevated minimum inhibitory concentrations. This trait confers selective advantage to the bacterium in the presence of fluoroquinolones.³¹

Risk Factors for Human Illness

Poultry consumption—The initial epidemiologic studies of sporadic campylobacteriosis conducted in the United States³²⁻³⁴ and western Europe³⁵⁻³⁷ revealed robust associations with the handling^{32,35} and consumption of poultry^{34,36,37} and particularly the consumption of undercooked poultry.^{33,38} More recent epidemiologic studies in the United States,³⁹ United Kingdom,⁴⁰ and New Zealand⁴¹ confirmed the association between human campylobacteriosis and poultry consumption and added an additional nuance: an association between *Campylobacter* infection and eating commercially prepared poultry.³⁹ These associations are not unexpected given data that most chicken in stores is contaminated with *C jejuni*.⁴² Molecular subtyping studies^{28,43} demonstrate partial correspondence between poultry and human isolates. In Quebec, for example, 20% of genotypes from humans and poultry had matching pulsed-field gel electrophoresis patterns.⁴⁴

Consumption of other commercially prepared foods—As noted, case-control studies^{39,41} in the United States and nations of the British Commonwealth have revealed that eating chicken in restaurants is associated with increased risk of infection. On occasion, other foods prepared in restaurants or commercial kitchens (eg, tuna salad,⁴⁵ sweet potatoes,⁴⁶ and lettuce⁴⁷) have been implicated in outbreaks of campylobacteriosis. Cross-contamination during food preparation is typically suspected to be a contributory factor in such outbreaks, and studies⁴⁸ clearly show that *C jejuni* can survive on food contact surfaces and thereby cross-contaminate other foods.

Other food items—In addition to poultry, several types of meat have been epidemiologically implicated as sources of *Campylobacter* spp in developed nations. Some of these implicated food items include pork loins, barbecued foods,⁴⁹ and liver pâté.⁵⁰

Unpasteurized milk—Drinking unpasteurized milk is a primary risk factor for outbreaks of campylobacterio-

sis. Between 1981 and 1990, 20 outbreaks of enteritis were reported in the United States.³¹ Of these outbreaks, 14 (70%) occurred among children who drank unpasteurized milk on school field trips or other youth activities. Unlike sporadic *Campylobacter* infections, which peak during the summer and are also associated with exposures such as eating chicken, eating at restaurants, and international travel, milk-associated outbreaks have a bimodal seasonality, with peaks during the spring and fall corresponding with the peak seasons for youth activities such as school field trips. Despite regulatory efforts to address the hazard, unpasteurized milk-associated outbreaks continue to occur.³² Recently, molecular typing studies^{32,33} have linked outbreak-associated infectious strains with unpasteurized milk from implicated dairies.

Water—One of the first case-control studies³⁸ of campylobacteriosis, which was conducted in Colorado, found an association between campylobacteriosis and the consumption of untreated surface water. More recently, a study⁵⁰ conducted in England found that people with *C. coli* infection were more likely to report drinking bottled water than were those with *C. jejuni* infection. In industrialized nations, waterborne outbreaks of campylobacteriosis typically involve lapses in community water sanitation.^{54,55}

Zoonotic transmission—Case-control studies^{34-36,38,56} identify contact with pet dogs and cats, and especially juvenile or diarrheic pets, as risk factors for *Campylobacter* infection, accounting for perhaps 5% of campylobacteriosis in humans. The hazard of zoonotic transmission may be greatest for young children, an age group with high rates of infection.⁵⁷ In 1 case report,⁵⁸ for example, a 3-week-old girl in a household with a recently acquired Labrador Retriever puppy developed *C. jejuni* bacteremia. Amplified fragment-length polymorphism analysis confirmed that the human and canine isolates were genetically similar. In an Australian case-control study, children < 3 years of age who lived in a home with a pet puppy had a 17-fold increase in risk of campylobacteriosis, compared with children with no puppy. Higher risk of campylobacteriosis in young children was also associated with ownership of pet chickens.⁵⁹ Occupational risk factors for campylobacteriosis include farm residence, poultry occupation, and daily contact with chickens.⁴⁹

Foreign travel—Foreign travel is a commonly reported risk factor for campylobacteriosis.^{28,40,41} In Sweden, where *Campylobacter* contamination of poultry meat is uncommon, international travel has traditionally accounted for approximately 75% of human *Campylobacter* infections.³⁵ In the United States, it is estimated that between 20 and 25% of *Campylobacter* infections are acquired during international travel.⁴ Campylobacteriosis was the most frequently reported enteric bacterial infection in Austrian tourists returning from southern Europe and Asia.⁶⁰ In England, travel to South Africa was associated with *C. coli* infection.⁵⁰ The causal exposures for travel-associated infections remain to be determined (eg, food, beverage, dining venue, antimicrobial usage, or animal contact).

Antimicrobial usage—In a Hawaiian case-control study,³⁹ use of antimicrobials in the month prior to

onset of illness was associated with campylobacteriosis, a unique finding in studies to date. One hypothesis for the observation is that antimicrobial usage lowers the infectious dose of drug-resistant *C. jejuni* strains. Another potential explanation is that the use of antimicrobials may alter colonic flora, resulting in decreased resistance to infection even with antimicrobial-susceptible *C. jejuni* strains.

Campylobacter Ecology

Survival in the environment—*Campylobacter jejuni* is adapted to the intestinal tract of warm-blooded animals and does not normally replicate outside this environmental niche.⁶¹ In humans, the infectious dose is reported to be < 1,000 *Campylobacter* organisms.⁶² Other adaptations to an intestinal niche include a single polar flagellum and corkscrew shape (Fig 1). These traits facilitate motility in the viscous intestinal mucous. Requirements for growth in the laboratory⁶¹ also reflect this narrow ecologic niche: a microaerophilic nitrogen atmosphere with low oxygen (5 to 7%) and high carbon dioxide tension (7 to 13%). Optimal replication of *C. jejuni* occurs under conditions similar to those in the lower intestinal tract of mammals (eg, 37°C and pH 4.9). The bacterium is also sensitive to desiccation and osmotic stress (eg, NaCl concentrations > 2%).

The bacterium gradually dies outside the host intestinal tract. In 1 study,⁶³ 58 of 85 (68%) *C. jejuni* strains could not be isolated from water after 3 weeks; however, a few strains were detected in unstirred water after 60 days. Environmental factors may facilitate *Campylobacter* survival under adverse conditions. Survival times are longer in nutrient-rich water than in deionized water.⁶⁴ Similarly, biofilms are reported to facilitate the survival of *C. jejuni* in broiler houses.⁶⁵ Some researchers postulate that campylobacters can survive in water in a viable but noncultivable form^{66,67}; however, the role of this dormant stage in the *Campylobacter* life cycle is controversial.⁶⁸

Animal Sources

Poultry—Although not all poultry flocks become colonized during the production cycle, *C. jejuni* is




Figure 1—Scanning electron micrograph of the single polar flagellum and corkscrew shape of *Campylobacter jejuni*. These morphologic characteristics contribute to the characteristic darting motility of *C. jejuni* in the viscous mucous layer of the intestinal lumen.

introduced into many broiler flocks during the production cycle.⁶⁹⁻⁷¹ Horizontal transmission appears to play an important role in the natural history of *C jejuni* in poultry operations.⁷² Risk factors for flock colonization include seasonality, caretakers who work with other animals, and drinking-water sanitation.^{73,74} Associations are also reported with type of air-handling system and degree of beetle infestation.⁷⁵ Infections spread rapidly within flocks after introduction. Colonization typically occurs by 3 to 4 weeks of age.^{76,77} Although most campylobacters do not survive in cleaned and disinfected houses,⁷⁷ certain strains appear to persist in successive broiler flock rotations.⁷⁸ Recent studies⁷⁹ suggest that the crop is among the most frequently infected organs of broilers entering processing plants, with overall crop carriage rates on the order of 60%, similar to the frequency of contamination reported on broiler carcasses after processing.⁴²

Cattle, sheep, and swine—*Campylobacter* species often inhabit the bovine intestinal tract, particularly of calves. In a Swiss study,⁸⁰ the overall prevalence of *C jejuni* in calves during the first 3 months of life on large cow-calf farms was 39%. In a Danish study,⁸¹ 20 of 24 cattle herds were infected, and young animals had a higher prevalence than older animals. In 40% of infected herds, all *C jejuni* isolates had the identical serotype and pulsed-field gel electrophoresis type. In a California study,⁸² prevalence of *Campylobacter* infection in a multiple-herd study of adult beef cattle was 5%. The number of adult cows on the farm was positively associated with the proportion that tested positive.

In a study of sheep raised around Lancaster, England, *C jejuni* accounted for 90% of all campylobacters isolated from fecal specimens. Three hundred thirty of 360 (92%) sheep were intestinal carriers of campylobacters at the processing plant. Among pastured sheep, the lowest incidence of fecal shedding was seen in lowland pastured sheep (94 of 390 [24%]), and the highest rate of fecal shedding was seen in salt marsh pastured sheep (122 of 240 [51%]). The highest incidence of shedding (30 of 30 [100%] fecal specimens) coincided with spring lambing, movement of ewes onto pasture after weaning, and fall weaning. The lowest incidence (0 of 30 [0%]) occurred between November and March among sheep fed on hay or silage.⁸³

Campylobacter coli is the predominant *Campylobacter* sp of swine. In a study⁸⁴ of fecal specimens from healthy Belgian swine, 61 of 65 (94%) *Campylobacter* isolates were *C coli*. A Dutch study⁸⁵ suggests that strict breeding management (eg, the use of high-efficiency particulate air filters and isolation of sows) can eliminate most *C coli* in swine operations by breaking the chain of transmission from sows to piglets. These findings related to strict controls and may not be applicable to commercial swine industries.

Wildlife—The evidence that wildlife is an important reservoir for human *Campylobacter* infections is equivocal. To be a substantial source of human infections, feces from wildlife would need to enter the human food or water supply. Although some wild birds are colonized with *Campylobacter*, a Danish

study⁸⁶ of *C jejuni* isolates indicated that the serotype distribution in wildlife was different from the distributions in broilers and humans. *Campylobacter jejuni* contamination rates in wild bird-associated specimens vary markedly—between 0 and 50% in a US study.⁸⁷ The finding of *Campylobacter* in wildlife may also indicate contact with food animals. In a study⁸⁸ from Japan, 3 of 13 *C jejuni* isolates from sparrows were resistant to quinolone, suggesting that these sparrows acquired campylobacters from food animal populations.

Food and Water Sources

Retail meat and poultry—Surveillance programs to monitor retail foodborne hazards have been implemented in the United States.⁴² In 2002, FoodNet sites in the United States began routine retail food surveys to compare genotypic antimicrobial resistance patterns of campylobacters from human and food isolates. Ongoing surveillance will provide data for managing risks by type of retail meat and poultry product. In metropolitan Washington, DC, for example, 130 of 184 (71%) packages of chicken sold at retail outlets contained *C jejuni* or *C coli*, followed by 4% of 172 turkey packages and < 2% of pork and beef packages.⁴² Another US study⁸⁹ of more than 2,000 lamb carcasses from 6 large processing plants showed that < 1% were contaminated with *C jejuni* or *C coli*. In an English study³ of nearly 500 retail specimens, chicken meat had the highest contamination rate (83%); however, the majority of lamb liver (73%), pork liver (72%), and beef liver (54%) was also contaminated. In that study, as expected, *C jejuni* was the predominant *Campylobacter* sp isolated from chicken meat (77%), and *C coli* was the predominant species isolated from pork liver (42%).

Milk and water—Surveys of bulk tank milk specimens indicate that unpasteurized milk is a source of *C jejuni*. In a study⁹⁰ conducted in Minnesota and South Dakota, approximately 10% of unpasteurized milk specimens from dairy bulk tanks was contaminated with *C jejuni*. Surface waters are often contaminated with campylobacters. In a Norwegian study,⁹¹ 32 of 60 water specimens from the Bo River contained campylobacters; *C coli* was detected more often than *C jejuni*. In that study, fecal coliforms were not a reliable indicator of low-level *Campylobacter* contamination.

Disease Prevention

On-farm controls—Efforts to reduce pathogen loads at the farm increase the likelihood that pathogen reduction steps at processing plants and in the kitchen will increase the safety of foods of animal origin. Investigations to reduce broiler intestinal colonization have been most actively pursued in Western Europe. In 1 study,⁹² biosecurity measures reduced *Campylobacter* colonization rates in flocks by half. Reduction in colonization was associated with use of disinfectant footbaths, daily water disinfection, and the location of ventilation units in the poultry production room. In another study,⁷⁴ cleaning and disin-

fection, change of footwear at the entrance to broiler houses, and control of vermin were associated with substantially lower rates of *Campylobacter* colonization in broiler flocks.

Several studies have focused on interventions during broiler flock depopulation. In 1 study,⁹³ lactic acid treatment of drinking water during the 8-hour preslaughter feed withdrawal period reduced carcass contamination by 15%. Other studies^{69,94} indicated that colonization rates increased when flocks were depopulated in batches rather than all at once. Transport crates brought to the farm at the time of depopulation also appear to expose birds to campylobacters.⁹⁵

Competitive exclusion products have also been proposed to reduce broiler colonization. Various products containing defined poultry isolates of *C jejuni*,^{95,96} *Lactobacillus*,⁹⁷ and undefined cultures are reported to reduce colonization under experimental conditions.⁹⁸ Diet may also alter intestinal carbohydrates that affect the colonization potential of campylobacters.⁹⁹

Processing controls—Carcass processing is a promising site for pathogen reduction efforts. The microbial quality of broiler carcasses has been associated with the abattoir where processing occurred.⁶⁹ Treatment of wash water is a potential processing control to reduce contamination, and the microbial quality of poultry wash water is thought to contribute to higher contamination rates of poultry than red meat.⁶⁹ In 1 study,¹⁰⁰ the use of electrolyzed water for washing poultry carcasses resulted in a 3 log₁₀ reduction of *C jejuni* counts on chicken. In another study,¹⁰¹ washing poultry skin in 10% oleic acid significantly reduced the number of campylobacters that remained attached to poultry skin. Campylobacters are also sensitive to active chlorine.¹⁰² The chlorination of carcass wash water, an important component of the HACCP programs in processing plants,¹⁰³ may have contributed to the decline in human campylobacteriosis in the United States since the mid-1990s.⁶ Postprocessing interventions have also been investigated. Compared with refrigeration, freezing poultry carcasses to -20°C reduced *Campylobacter* counts by 2 log₁₀.¹⁰⁴ Electron beam irradiation of poultry would virtually eliminate campylobacters from poultry products; however, some consumers report that the color and texture of chicken fillets are altered by irradiation.¹⁰⁵ If these food-quality issues can be successfully resolved, irradiation of poultry products may become among the most important technologies for the prevention of foodborne campylobacteriosis in the United States.

Food handling—Veterinarians who specialize in food safety address hazards in the food chain from the farm to the consumer, including the promotion of safe food-handling practices. Surveys conducted in the United States indicate that safe food-handling skills could be improved in several demographic groups, including males and young adults.¹⁰⁶ In addition, food handling is the last control point in the farm-to-table food safety continuum for preventing foodborne

campylobacteriosis. One useful source of safe food-handling information is the Partnership for Food Safety Education Web site (www.fightbac.org). Studies indicate that restaurants³⁹ and home kitchens³² are venues for the transmission of *C jejuni* to humans.⁴¹ Recommendations for kitchen sanitation emphasize cleaning and disinfection of food contact surfaces, hands, and utensils following contact with raw meat and poultry. In addition, raw meat and poultry should be stored separately from foods that will be served without subsequent cooking. Meat thermometers are recommended to measure the internal temperature of meat and poultry. Poultry should be heated to an internal temperature of 82°C (180°F) to kill campylobacters. Veterinarians are also in a unique position to discourage the public from selling or buying unpasteurized milk.

Zoonosis prevention—Handwashing after animal contact is a prudent step to prevent zoonotic transmission of campylobacters in household and occupational settings. Additional sanitary precautions are recommended with juvenile or diarrhetic pets. It is particularly important to ensure that children wash their hands after animal contact.¹⁰⁷ Working together, veterinarians and other health care providers can formulate a plan of hygienic precautions that will permit most immunocompromised patients to safely enjoy animal companionship.¹⁰⁸

Conclusion

It is humbling that a bacterium as sensitive to physiologic stress as *C jejuni* remains a common cause of foodborne infection in the new millennium. Well-defined hazards for the transmission of campylobacters exist in the environment and food chain (Fig 2). Because no single intervention will eliminate all of these hazards, a combination of prevention efforts is needed related to animal contact—on farms, in processing plants, and in kitchens. When considering options for pathogen reduction, it is important to balance cost and effectiveness; however, cost should not be an excuse for inaction. If the veterinary profession takes an active leadership role, it is uniquely poised to contribute to reduction in the burden of human campylobacteriosis.




Figure 2—A model of the life cycle of *C jejuni* depicting suspected environmental, food, and animal sources and putative virulence determinants for infection of susceptible hosts.

References

1. Escherich T. Über das Vorkommen von Vibrionen im Darmkanal und den Stuhlgängen der Säuglinge. *Munch Med Wochenschr* 1886;33:815–817, 833–835.
2. DeKeyser P, Gossuin-Detrain M, Butzler JP, et al. Acute enteritis due to related vibrio: first positive stool cultures. *J Infect Dis* 1972;125:390–392.
3. Kramer JM, Frost JA, Bolton FJ, et al. *Campylobacter* contamination of raw meat and poultry at retail sale: identification of multiple types and comparison with isolates from human infection. *J Food Prot* 2000;63:1654–1659.
4. Centers for Disease Control and Prevention. National Antimicrobial Resistance Monitoring System Worldwide Web site. Available at: www.cdc.gov/narms/pus/camp.htm. Accessed January 30, 2003.
5. Mead PS, Slutsker L, Dietz V, et al. Food-related illness and death in the United States. *Emerg Infect Dis* 1999;5:607–625.
6. Centers for Disease Control and Prevention. Preliminary FoodNet data on the incidence of foodborne illnesses—selected sites, United States, 2001. *MMWR Morb Mortal Wkly Rep* 2002;51:325–329.
7. Blaser MJ. Epidemiologic and clinical features of *Campylobacter jejuni* infections. *J Infect Dis* 1997;176(suppl 2):S103–S105.
8. Blaser MJ, Szaz E, Williams LP Jr. The influence of immunity on raw milk-associated *Campylobacter* infection. *JAMA* 1987;257:43–46.
9. Walz SE, Baqar S, Beecham HJ, et al. Pre-exposure anti-*Campylobacter jejuni* immunoglobulin A levels associated with reduced risk of *Campylobacter* diarrhea in adults traveling to Thailand. *Am J Trop Med Hyg* 2001;65:652–656.
10. Pigrau C, Bartolome R, Almirante B, et al. Bacteremia due to *Campylobacter* species: clinical findings and antimicrobial susceptibility patterns. *Clin Infect Dis* 1997;25:1414–1420.
11. Manfredi R, Nanetti A, Ferri M, et al. Fatal *Campylobacter jejuni* bacteraemia in patients with AIDS. *J Med Microbiol* 1999;48:601–603.
12. Angulo FJ, Swerdlow DL. Bacterial enteric infections in persons infected with human immunodeficiency virus. *Clin Infect Dis* 1995;21(suppl 1):S84–S93.
13. Nachamkin I. Chronic effects of *Campylobacter* infection. *Microbes Infect* 2002;4:399–403.
14. Dingle KE, Van Den BN, Colles FM, et al. Sequence typing confirms that *Campylobacter jejuni* strains associated with Guillain-Barre and Miller-Fisher syndromes are of diverse genetic lineage, serotype, and flagella type. *J Clin Microbiol* 2001;39:3346–3349.
15. Yuki N, Tagawa Y, Irie F, et al. Close association of Guillain-Barre syndrome with antibodies to minor monosialogangliosides GM1b and GM1 alpha. *J Neuroimmunol* 1997;74:30–34.
16. Prendergast MM, Lastovica AJ, Moran AP. Lipopolysaccharides from *Campylobacter jejuni* O:41 strains associated with Guillain-Barre syndrome exhibit mimicry of GM1 ganglioside. *Infect Immun* 1998;66:3649–3655.
17. Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. *Ann Neurol* 1999;45:168–173.
18. Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. *Ann Neurol* 1996;40:635–644.
19. Goodyear CS, O'Hanlon GM, Plomp JJ, et al. Monoclonal antibodies raised against Guillain-Barre syndrome-associated *Campylobacter jejuni* lipopolysaccharides react with neuronal gangliosides and paralyze muscle-nerve preparations. *J Clin Invest* 1999;104:697–708.
20. Rees JH, Vaughan RW, Kondeatis E, et al. HLA-class II alleles in Guillain-Barre syndrome and Miller Fisher syndrome and their association with preceding *Campylobacter jejuni* infection. *J Neuroimmunol* 1995;62:53–57.
21. Hughes RA. Systematic reviews of treatment for inflammatory demyelinating neuropathy. *J Anat* 2002;200:331–339.
22. Hannu T, Mattila L, Rautelin H, et al. *Campylobacter*-triggered reactive arthritis: a population-based study. *Rheumatology (Oxford)* 2002;41:312–318.
23. Loch H, Krogfelt KA. Comparison of rheumatological and gastrointestinal symptoms after infection with *Campylobacter jejuni/coli* and enterotoxigenic *Escherichia coli*. *Ann Rheum Dis* 2002;61:448–452.
24. American Veterinary Medical Association. FDA hastening withdrawal of fluoroquinolone approvals for poultry. *J Am Vet Med Assoc* 2000;217:1447, 1452.
25. Food and Drug Administration. Risk assessment on the human health impact of fluoroquinolone resistant *Campylobacter* associated with the consumption of chicken, October 18, 2000. Available at: www.fda.gov/cvm/antimicrobial/Risk_asses.htm. Accessed January 30, 2003.
26. Friedman CR, Niemann J, Wegener HC, et al. Epidemiology of *Campylobacter jejuni* infections in the United States and other industrialized nations. In: Nachamkin I, Blaser MJ, eds. *Campylobacter*. 2nd ed. Washington, DC: American Society for Microbiology, 2000;121–138.
27. Marano NN, Rossiter S, Stamey K, et al. The National Antimicrobial Resistance Monitoring System (NARMS) for enteric bacteria, 1996–1999: surveillance for action. *J Am Vet Med Assoc* 2000;217:1829–1830.
28. Smith KE, Besser JM, Hedberg CW, et al. Quinolone-resistant *Campylobacter jejuni* infections in Minnesota, 1992–1998. Investigation team. *N Engl J Med* 1999;340:1525–1532.
29. Engberg J, Aarestrup FM, Taylor DE, et al. Quinolone and macrolide resistance in *Campylobacter jejuni* and *C. coli*: resistance mechanisms and trends in human isolates. *Emerg Infect Dis* 2001;7:24–34.
30. Hooper DC, Wolfson JS, Ng EY, et al. Mechanisms of action of and resistance to ciprofloxacin. *Am J Med* 1987;82:12–20.
31. McDermott PF, Bodeis SM, English LL, et al. Ciprofloxacin resistance in *Campylobacter jejuni* evolves rapidly in chickens treated with fluoroquinolones. *J Infect Dis* 2002;185:837–840.
32. Hopkins RS, Scott AS. Handling raw chicken as a source for sporadic *Campylobacter jejuni* infections (lett). *J Infect Dis* 1983;148:770.
33. Harris NV, Weiss NS, Nolan CM. The role of poultry and meats in the etiology of *Campylobacter jejuni/coli* enteritis. *Am J Public Health* 1986;76:407–411.
34. Deming MS, Tauxe RV, Blake PA, et al. *Campylobacter* enteritis at a university: transmission from eating chicken and from cats. *Am J Epidemiol* 1987;126:526–534.
35. Norkrans G, Svedhem A. Epidemiological aspects of *Campylobacter jejuni* enteritis. *J Hyg (Lond)* 1982;89:163–170.
36. Kapperud G, Skjerve E, Bean NH, et al. Risk factors for sporadic *Campylobacter* infections: results of a case-control study in southeastern Norway. *J Clin Microbiol* 1992;30:3117–3121.
37. Oosterom J, den Uyl CH, Banffer JR, et al. Epidemiological investigations on *Campylobacter jejuni* in households with a primary infection. *J Hyg (Lond)* 1984;93:325–332.
38. Hopkins RS, Olmsted R, Istre GR. Endemic *Campylobacter jejuni* infection in Colorado: identified risk factors. *Am J Public Health* 1984;74:249–250.
39. Effler P, Ieong MC, Kimura A, et al. Sporadic *Campylobacter jejuni* infections in Hawaii: associations with prior antibiotic use and commercially prepared chicken. *J Infect Dis* 2001;183:1152–1155.
40. Rodrigues LC, Cowden JM, Wheeler JG, et al. The study of infectious intestinal disease in England: risk factors for cases of infectious intestinal disease with *Campylobacter jejuni* infection. *Epidemiol Infect* 2001;127:185–193.
41. Eberhart-Phillips J, Walker N, Garrett N, et al. *Campylobacteriosis* in New Zealand: results of a case-control study. *J Epidemiol Community Health* 1997;51:686–691.
42. Zhao C, Ge B, De Villena J, et al. Prevalence of *Campylobacter* spp, *Escherichia coli*, and *Salmonella* serovars in retail chicken, turkey, pork, and beef from the Greater Washington, D.C., area. *Appl Environ Microbiol* 2001;67:5431–5436.
43. Hanninen ML, Perko-Makela P, Pitkala A, et al. A three-year study of *Campylobacter jejuni* genotypes in humans with domestically acquired infections and in chicken samples from the Helsinki area. *J Clin Microbiol* 2000;38:1998–2000.
44. Nadeau E, Messier S, Quessy S. Prevalence and comparison of genetic profiles of *Campylobacter* strains isolated from poultry and

sporadic cases of campylobacteriosis in humans. *J Food Prot* 2002; 65:73–78.

45. Roels TH, Wickus B, Bostrom HH, et al. A foodborne outbreak of *Campylobacter jejuni* (O:33) infection associated with tuna salad: a rare strain in an unusual vehicle. *Epidemiol Infect* 1998;121: 281–287.

46. Winquist AG, Roome A, Mshar R, et al. Outbreak of campylobacteriosis at a senior center. *J Am Geriatr Soc* 2001;49: 304–307.

47. Centers for Disease Control and Prevention. Outbreak of *Campylobacter* enteritis associated with cross-contamination of food—Oklahoma, 1996. *JAMA* 1998;279:1341.

48. Cogan TA, Bloomfield SF, Humphrey TJ. The effectiveness of hygiene procedures for prevention of cross-contamination from chicken carcasses in the domestic kitchen. *Lett Appl Microbiol* 1999; 29:354–358.

49. Studahl A, Andersson Y. Risk factors for indigenous *Campylobacter* infection: a Swedish case-control study. *Epidemiol Infect* 2000;125:269–275.

50. Gillespie IA, O'Brien SJ, Frost JA, et al. A case-case comparison of *Campylobacter coli* and *Campylobacter jejuni* infection: a tool for generating hypotheses. *Emerg Infect Dis* 2002;8: 937–942.

51. Wood RC, MacDonald KL, Osterholm MT. *Campylobacter* enteritis outbreaks associated with drinking raw milk during youth activities. A 10-year review of outbreaks in the United States. *JAMA* 1992;268:3228–3230.

52. Centers for Disease Control and Prevention. Outbreak of *Campylobacter jejuni* infections associated with drinking unpasteurized milk procured through a cow-leasing program—Wisconsin, 2001. *MMWR Morb Mortal Wkly Rep* 2002;51:548–549.

53. Lehner A, Schneck C, Feierl G, et al. Epidemiologic application of pulsed-field gel electrophoresis to an outbreak of *Campylobacter jejuni* in an Austrian youth centre. *Epidemiol Infect* 2000;125:13–16.

54. Melby KK, Svendby JG, Eggebo T, et al. Outbreak of *Campylobacter* infection in a subarctic community. *Eur J Clin Microbiol Infect Dis* 2000;19:542–544.

55. Sacks JJ, Lieb S, Baldy LM, et al. Epidemic campylobacteriosis associated with a community water supply. *Am J Public Health* 1986;76:424–428.

56. Saeed AM, Harris NV, DiGiacomo RF. The role of exposure to animals in the etiology of *Campylobacter jejuni/coli* enteritis. *Am J Epidemiol* 1993;137:108–114.

57. Tauxe RV, Hargrett-Bean N, Patton CM, et al. *Campylobacter* isolates in the United States, 1982–1986. *MMWR CDC Surveill Summ* 1988;37:1–13.

58. Wolfs TF, Duim B, Geelen SP, et al. Neonatal sepsis by *Campylobacter jejuni*: genetically proven transmission from a household puppy. *Clin Infect Dis* 2001;32:E97–E99.

59. Tenkate TD, Stafford RJ. Risk factors for *Campylobacter* infection in infants and young children: a matched case-control study. *Epidemiol Infect* 2001;127:399–404.

60. Reinthaler FF, Feierl G, Stunzner D, et al. Diarrhea in returning Austrian tourists: epidemiology, etiology, and cost-analysis. *J Travel Med* 1998;5:65–72.

61. Nachamkin I. *Campylobacter* and *Arcobacter*. In: Murray PR, Baron EJ, Pfaller MA, et al, eds. *Manual of clinical microbiology*. Washington, DC: American Society for Microbiology, 2003;902–914.

62. Black RE, Levine MM, Clements ML, et al. Experimental *Campylobacter jejuni* infection in humans. *J Infect Dis* 1988;157: 472–479.

63. Talibart R, Denis M, Castillo A, et al. Survival and recovery of viable but noncultivable forms of *Campylobacter* in aqueous microcosm. *Int J Food Microbiol* 2000;55:263–267.

64. Thomas C, Hill DJ, Mabey M. Evaluation of the effect of temperature and nutrients on the survival of *Campylobacter* spp. in water microcosms. *J Appl Microbiol* 1999;86:1024–1032.

65. Trachoo N, Frank JF, Stern NJ. Survival of *Campylobacter jejuni* in biofilms isolated from chicken houses. *J Food Prot* 2002; 65:1110–1116.

66. Thomas C, Hill D, Mabey M. Culturability, injury and morphological dynamics of thermophilic *Campylobacter* spp within a laboratory-based aquatic model system. *J Appl Microbiol* 2002;92:433–442.

67. Cappelier JM, Rossero A, Federighi M. Demonstration of a protein synthesis in starved *Campylobacter jejuni* cells. *Int J Food Microbiol* 2000;55:63–67.

68. van de Giessen AW, Heuvelman CJ, Abee T, et al. Experimental studies on the infectivity of non-culturable forms of *Campylobacter* spp. in chicks and mice. *Epidemiol Infect* 1996; 117:463–470.

69. Wedderkopp A, Rattenborg E, Madsen M. National surveillance of *Campylobacter* in broilers at slaughter in Denmark in 1998. *Avian Dis* 2000;44:993–999.

70. Stern NJ, Fedorka-Cray P, Bailey JS, et al. Distribution of *Campylobacter* spp in selected U.S. poultry production and processing operations. *J Food Prot* 2001;64:1705–1710.

71. Denis M, Refregier-Petton J, Laisney MJ, et al. *Campylobacter* contamination in French chicken production from farm to consumers. Use of a PCR assay for detection and identification of *Campylobacter jejuni* and *Camp coli*. *J Appl Microbiol* 2001;91: 255–267.

72. Jacobs-Reitsma WF, van de Giessen AW, Bolder NM, et al. Epidemiology of *Campylobacter* spp at two Dutch broiler farms. *Epidemiol Infect* 1995;114:413–421.

73. Kapperud G, Skjerve E, Vik L, et al. Epidemiological investigation of risk factors for *Campylobacter* colonization in Norwegian broiler flocks. *Epidemiol Infect* 1993;111:245–255.

74. van de Giessen AW, Bloemberg BR, Ritmeester WS, et al. Epidemiological study on risk factors and risk reducing measures for *Campylobacter* infections in Dutch broiler flocks. *Epidemiol Infect* 1996;117:245–250.

75. Refregier-Petton J, Rose N, Denis M, et al. Risk factors for *Campylobacter* spp contamination in French broiler-chicken flocks at the end of the rearing period. *Prev Vet Med* 2001;50:89–100.

76. Shreeve JE, Toszeghy M, Pattison M, et al. Sequential spread of *Campylobacter* infection in a multipen broiler house. *Avian Dis* 2000;44:983–988.

77. Evans SJ, Sayers AR. A longitudinal study of *Campylobacter* infection of broiler flocks in Great Britain. *Prev Vet Med* 2000;46: 209–223.

78. Petersen L, Wedderkopp A. Evidence that certain clones of *Campylobacter jejuni* persist during successive broiler flock rotations. *Appl Environ Microbiol* 2001;67:2739–2745.

79. Byrd JA, Corrier DE, Hume ME, et al. Effect of feed withdrawal on *Campylobacter* in the crops of market-age broiler chickens. *Avian Dis* 1998;42:802–806.

80. Busato A, Hofer D, Lentze T, et al. Prevalence and infection risks of zoonotic enteropathogenic bacteria in Swiss cow-calf farms. *Vet Microbiol* 1999;69:251–263.

81. Nielsen EM. Occurrence and strain diversity of thermophilic campylobacters in cattle of different age groups in dairy herds. *Lett Appl Microbiol* 2002;35:85–89.

82. Hoar BR, Atwill ER, Elmi C, et al. An examination of risk factors associated with beef cattle shedding pathogens of potential zoonotic concern. *Epidemiol Infect* 2001;127:147–155.

83. Jones K, Howard S, Wallace JS. Intermittent shedding of thermophilic campylobacters by sheep at pasture. *J Appl Microbiol* 1999;86:531–536.

84. Van Looveren M, Daube G, De Zutter L, et al. Antimicrobial susceptibilities of *Campylobacter* strains isolated from food animals in Belgium. *J Antimicrob Chemother* 2001;48:235–240.

85. Weijtens MJ, Uurlings HA, Van der PJ. Establishing a *Campylobacter*-free pig population through a top-down approach. *Lett Appl Microbiol* 2000;30:479–484.

86. Petersen L, Nielsen EM, Engberg J, et al. Comparison of genotypes and serotypes of *Campylobacter jejuni* isolated from Danish wild mammals and birds and from broiler flocks and humans. *Appl Environ Microbiol* 2001;67:3115–3121.

87. Craven SE, Stern NJ, Line E, et al. Determination of the incidence of *Salmonella* spp, *Campylobacter jejuni*, and *Clostridium perfringens* in wild birds near broiler chicken houses by sampling intestinal droppings. *Avian Dis* 2000;44:715–720.

88. Chuma T, Hashimoto S, Okamoto K. Detection of thermophilic *Campylobacter* from sparrows by multiplex PCR: the role of sparrows as a source of contamination of broilers with *Campylobacter*. *J Vet Med Sci* 2000;62:1291–1295.

89. Duffy EA, Belk KE, Sofos JN, et al. Microbial contamination

occurring on lamb carcasses processed in the United States. *J Food Prot* 2001;64:503-508.

90. Jayarao BM, Henning DR. Prevalence of foodborne pathogens in bulk tank milk. *J Dairy Sci* 2001;84:2157-2162.

91. Rosef O, Rettedal G, Lageide L. Thermophilic campylobacters in surface water: a potential risk of campylobacteriosis. *Int J Environ Health Res* 2001;11:321-327.

92. Gibbens JC, Pascoe SJ, Evans SJ, et al. A trial of biosecurity as a means to control *Campylobacter* infection of broiler chickens. *Prev Vet Med* 2001;48:85-99.

93. Byrd JA, Hargis BM, Caldwell DJ, et al. Effect of lactic acid administration in the drinking water during preslaughter feed withdrawal on *Salmonella* and *Campylobacter* contamination of broilers. *Poult Sci* 2001;80:278-283.

94. Hald B, Rattenborg E, Madsen M. Role of batch depletion of broiler houses on the occurrence of *Campylobacter* spp in chicken flocks. *Lett Appl Microbiol* 2001;32:253-256.

95. Slader J, Domingue G, Jorgensen F, et al. Impact of transport crate reuse and of catching and processing on *Campylobacter* and *Salmonella* contamination of broiler chickens. *Appl Environ Microbiol* 2002;68:713-719.

96. Chen HC, Stern NJ. Competitive exclusion of heterologous *Campylobacter* spp in chicks. *Appl Environ Microbiol* 2001;67:848-851.

97. Chang MH, Chen TC. Reduction of *Campylobacter jejuni* in a simulated chicken digestive tract by Lactobacilli cultures. *J Food Prot* 2000;63:1594-1597.

98. Hakkinen M, Schneitz C. Efficacy of a commercial competitive exclusion product against *Campylobacter jejuni*. *Br Poult Sci* 1999;40:619-621.

99. Fernandez F, Sharma R, Hinton M, et al. Diet influences the

colonisation of *Campylobacter jejuni* and distribution of mucin carbohydrates in the chick intestinal tract. *Cell Mol Life Sci* 2000;57:1793-1801.

100. Park H, Hung YC, Brackett RE. Antimicrobial effect of electrolyzed water for inactivating *Campylobacter jejuni* during poultry washing. *Int J Food Microbiol* 2002;72:77-83.

101. Hinton A Jr, Ingram KD. Use of oleic acid to reduce the population of the bacterial flora of poultry skin. *J Food Prot* 2000;63:1282-1286.

102. Yang H, Li Y, Johnson MG. Survival and death of *Salmonella typhimurium* and *Campylobacter jejuni* in processing water and on chicken skin during poultry scalding and chilling. *J Food Prot* 2001;64:770-776.

103. Hulebak KL, Schlosser W. Hazard analysis and critical control point (HACCP) history and conceptual overview. *Risk Anal* 2002;22:547-552.

104. Stern NJ, Rothenberg PJ, Stone JM. Enumeration and reduction of *Campylobacter jejuni* in poultry and red meats. *J Food Prot* 1985;48:606-610.

105. Lewis SJ, Velasquez A, Cuppett SL, et al. Effect of electron beam irradiation on poultry meat safety and quality. *Poult Sci* 2002;81:896-903.

106. Altekruze SF, Yang S, Timbo BB, et al. A multi-state survey of consumer food-handling and food-consumption practices. *Am J Prev Med* 1999;16:216-221.

107. Friedman CR, Torigian C, Shillam PJ, et al. An outbreak of salmonellosis among children attending a reptile exhibit at a zoo. *J Pediatr* 1998;132:802-807.

108. Angulo FJ, Glaser CA, Juranek DD, et al. Caring for pets of immunocompromised persons. *J Am Vet Med Assoc* 1994;205:1711-1718.



Zoonosis Updates, Second Edition

Zoonosis Update articles published in the Journal of the AVMA are available for easy access to authoritative information on diseases of concern to your clients and others in your community.

Price per copy: \$12 for AVMA members; \$20 for nonmembers (Please add \$6.00 for shipping and handling)

AVMA member? Yes No No. of copies _____ Total remittance enclosed \$ _____

(Payment must accompany order)

Name _____

Street Address _____

City _____ State _____ ZIP _____

Complete form and mail to: AVMA, 1931 N. Meacham Rd, Ste 100, Schaumburg, IL 60173